Clinical trial · Observational
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Lymphomas are hematological malignancies, which are divided into non-Hodgkin lymphoma and Hodgkin lymphoma. Non hodgkin lymphoma is a lymphoma-derived malignancy that makes up about 90% of all malignant lymphoma. According to its origin, non hodgkin lymphoma is classified into B-cell non hodgkin lymphoma and T-cell non hodgkin lymphoma. The most common types are follicular lymphoma, and diffuse large B-cell lymphoma. Lymphomas are types of cancer that develops from lymphocytes, a type of white blood cell. Diagnosis is by examination of a bone marrow or lymph node biopsy. Non hodgkin lymphoma mortality has increased in recent years and has become the seventh most frequently occurring cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bone marrow puncture and venous blood samples | Other | — | UNRESOLVED |
| venous blood samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Non hodgkin lymphoma patients
- description
- bone marrow puncture and venous blood samples
- interventionNames
- Other: bone marrow puncture and venous blood samples
- label
- healthy voulnteers
- description
- venous blood samples
- interventionNames
- Other: venous blood samples
Primary outcomes (1)
- measure
- mean difference of micro ribosomal nucleic acid 155 expression levels between samples of both non hodgkin lymphoma patients and healthy controls
- timeFrame
- 6 months
- description
- measuring levels of micro ribosomal nucleic acid 155 in peripheral blood and bone marrow samples of non hodgkin lymphoma patients and in peripheral blood samples of healthy controls
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Non hodgkin lymphoma patients of any age or sex. * healthy volunteers within the same range of age. Exclusion Criteria: * patients with any other haematological malignancy.
References
Publications (4)
- BACKGROUNDEkstrom-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma--a review. Acta Oncol. 2006;45(3):258-71. doi: 10.1080/02841860500531682. PMID 16644568
- BACKGROUNDNogai H, Dorken B, Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol. 2011 May 10;29(14):1803-11. doi: 10.1200/JCO.2010.33.3252. Epub 2011 Apr 11. PMID 21483013
- BACKGROUNDWillis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood. 2000 Aug 1;96(3):808-22. No abstract available. PMID 10910891
- BACKGROUNDJansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012 Dec;6(6):590-610. doi: 10.1016/j.molonc.2012.09.006. Epub 2012 Oct 9. PMID 23102669